Opus Genetics to Participate in Upcoming Medical and Industry Conferences in February 2026
Opus Genetics (NASDAQ:IRD) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $7.00 price target on the stock.
Opus Genetics Launches Gene Therapy Clinical Trial for MERTK-related Retinitis Pigmentosa
Opus Genetics (NASDAQ:IRD) was upgraded by analysts at BTIG Research to a "strong-buy" rating.
Opus Genetics (NASDAQ:IRD) is now covered by analysts at BTIG Research. They set a "buy" rating on the stock.